WHEAT RIDGE, CO and LOS ANGELES, CA--(MARKET WIRE)--Jan 6, 2009 -- GeneThera, Inc. (Other OTC:GTHR.PK - News), an innovator in the biotech marketplace, today released partial income projections for 2009 based on the new Johne’s disease test. The projections released are only for GeneThera Diagnostic Laboratories, the US testing division of GeneThera, Inc.
GeneThera is currently negotiating with a distribution company regarding marketing its upcoming Johne’s disease test. Based on these negotiations and the overall state of the market, the company has released the following budget forecast statement:
“There are approximately 17,000,000 dairy cattle in the US, which should each be tested for Johne’s disease annually. However, only one million tests (or less than 6%) are currently performed each year,” noted Dr. Tony Milici of GeneThera. “Prior to GeneThera’s test, traditional Johne’s tests involved multiple steps, were time consuming, required several parties, and took from 2 weeks to 4 months before test results were given. GeneThera’s innovative Real Time PCR diagnostic laboratories create a more accurate, timely, and affordable test due to GeneThera’s on-site laboratory. Our laboratory is independent and provides confidential results for our clients.”
Each year Dairy farmers with infected herds may be losing as much as $235 a year for every animal in their herd. In 2002, Purdue University scientists claimed it causes $1 Billion in cattle losses each year. Some states, like Wisconsin, provide up to $250,000 in reimbursements for Johne’s disease testing and the USDA has provided a nationwide grant.
“Utilizing our proprietary tests and newly developed Real Time PCR high throughput lab, we are expecting testing income for GeneThera Diagnostic Laboratories in 2009 to be somewhere in the range of $6-$10,000,000,” stated Dr. Milici. “We fully expect this number to increase exponentially should the Obama administration follow through with the USDA’s desired enforcement of the National Animal Identification System, or should a definitive link between Johne’s disease and Irritable Bowel Syndrome or Crohn’s disease be made public.”
GeneThera’s primary goal is to capture majority of the market share within the first year and continue to grow its market share significantly thereafter. With the cost of each test being only $15-$25 per test, the company states convenience and affordability of the testing service will be the biggest selling points for Dairy Farmers. This should prompt other farmers to begin testing their cattle who never have tested for Johne’s disease due to the inexpensive testing program.
ABOUT GENETHERA, INC.
GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company’s proprietary diagnostic solution is based on a genetic expression assay, GES™, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne’s disease. For more information, contact Dr. Tony Milici at 303-463-6371 or Al Goldsmith of The Goldsmith Group LLC at 303-838-4370.
This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “intends,” “believes,” and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
Contact:
Dr. Tony Milici 303-463-6371
Goldsmith Group 303-838-4370
JR Dopkin & Associates 516-884-3200
Source: GeneThera, Inc.
